Clinical outcome at 28 and 52 weeks
| Total number of patients (n=103) | Patients without detectable antiadalimumab antibodies (n=80) | Patients with detectable antiadalimumab antibodies (n=23) | p value* | RC (95% CI) | Adjusted p value† | Adjusted RC (95%CI)† | |
|---|---|---|---|---|---|---|---|
| Week 28 | |||||||
| DAS28, mean (SD) | 2.34 (1.25) | 2.16 (1.14) | 2.95 (1.44) | 0.007 | 0.8 (0.2–1.4) | 0.023 | 0.7 (0.1–1.4) |
| ESR mm/h, median (IQR)‡ | 5 (2–11) | 5 (2–10) | 10 (2–19) | 0.048 | 4.8 (0.0–9.7) | 0.055 | 5.2 (−0.1–10.6) |
| CRP mg/L, median (IQR)‡ | 2 (1–3) | 1 (1–3) | 3 (2–6) | 0.03 | 2.7 (0.3–5.1) | 0.016 | 3.2 (0.6–5.9) |
| PASI, median (IQR)‡ | 0 (0–0.8) | 0 (0–0.6) | 0.6 (0.3–1.6) | 0.069 | 0.5 (0.0–1.1) | 0.392 | 0.3 (−0.4–0.9) |
| Week 52 | |||||||
| DAS28, mean (SD) | 2.36 (1.28) | 2.19 (1.20) | 2.95 (1.41) | 0.011 | 0.8 (0.2–1.3) | 0.024 | 0.8 (0.1–1.4) |
| ESR mm/h, median (IQR)‡ | 5 (2–11) | 5 (2–10) | 6 (3–19) | 0.110 | 4.0 (−0.9–8.9) | 0.039 | 5.7 (0.3–11.2) |
| CRP mg/L, median (IQR)‡ | 1 (1–3) | 1 (1–3) | 3 (2–6) | 0.029 | 2.3 (0.2–4.3) | 0.014 | 2.7 (0.5–4.9) |
| PASI, median (IQR)‡ | 0 (0–0.8) | 0 (0–0.4) | 1 (0.4–2.2) | 0.002 | 1.0 (0.4–1.6) | 0.067 | 0.6 (0.0–1.3) |
*p value for patients without antidrug antibodies (ADA) vs patients with ADA, linear regression model.
†At weeks 28 and 52 for DAS28 and ESR confounders are methotrexate use and dosage, for CRP the confounder is methotrexate dose and for PASI methotrexate use was a confounder. Linear regression model.
‡A linear regression model was used without transformation of the data since the residuals were normally distributed.
CRP, c reactive protein; DAS28, 28-Joint Disease Activity Score; ESR, Erythrocyte Sedimentation Rate; PASI, Psoriasis Area Severity Index; RC, regression coefficient.